“I think our view is these underlying trends continue, and as respiratory headwinds moderate in Q4, we'll exit at that overall mid-single digit rate.”

In context

“to a diagnostics follow-up. The flat assumption for Q3, given the magnitude of the respiratory headwind that you're going to face, implies a step up in the core growth rate to high single digits from that 5% figure in Q4-- I'm sorry, in Q2. Could you elaborate on what drives that acceleration? Thank you. Matt Gugino Sure, Dan. Obviously, we have some variability here with the respiratory headwinds from quarter to quarter, but I think if you unpack it, excluding respiratory, diagnostics was solid, mid-single digits in the second quarter. I think we're encouraged by some of that execution we're seeing commercially across the platform, as well as some of those new product innovations that are driving accelerated growth, like that DxI 9000 at Beckman, the continued menu expansion at Cepheid. I think our view is these underlying trends continue, and as respiratory headwinds moderate in Q4, we'll exit at that overall mid-single digit rate. Remember here, Dan, we do have China policy, those headwinds are starting to lessen. You see a little bit lower of a headwind here in Q3 and Q4, which are driving a bit more of the overall step up as well. Operator Thank you. Our next question will come from Scott Davis with Melius Research. Please go ahead. Rainer M. Blair Thanks, Scott. Scott Davis Morning, Rainer and Matt and Rachel. Morning. Hey, you only owned Masimo for, I guess, a month, but can we get a little bit of an early read on it? Would you be willing to give us maybe the growth rate that they put up for the quarter or any information about it? That would be helpful. Rainer M. Blair Sure. First of all, Scott, thanks. We're really excited by the fact that we were able to get that acquisition closed a little bit earlier t”